Tags

Type your tag names separated by a space and hit enter

Treatment of Post-Coarctectomy Hypertension With Labetalol-A 9-Year Single-Center Experience.
World J Pediatr Congenit Heart Surg. 2022 11; 13(6):701-706.WJ

Abstract

BACKGROUND

Although considering the pathophysiology of post-coarctectomy hypertension, β-blockers should be effective, experience with labetalol for treatment is limited in the literature.

METHODS

Retrospective collection and analysis of data in children aged ≤6 years following coarctectomy in our tertiary care university medical center between January 2009 and June 2018.

RESULTS

96 patients were included, 45 were treated with intravenous labetalol and 51 received no treatment. Median time to maximum dose received (median 1.1 mg/kg/h) was 2.7 h, and median time to the reduction of labetalol dose was 8.3 h. No antihypertensives had to be added. In one child, labetalol was switched to nitroprusside due to bronchoconstriction. Of patients receiving intravenous labetalol, 48% had been switched to oral labetalol at discharge.

CONCLUSIONS

Intravenous labetalol is a fast, effective, and safe drug to treat hypertension following aortic coarctation repair. Labetalol is easily converted to oral therapy when the continuation of treatment is considered necessary.

Authors+Show Affiliations

Pediatric Intensive Care Unit, 4501Leiden University Medical Center, Leiden, the Netherlands.Pediatric Intensive Care Unit, 4501Leiden University Medical Center, Leiden, the Netherlands.Department of Thoracic Surgery, 4501Leiden University Medical Center, Leiden, the Netherlands.Willem Alexander Children's Hospital - Division of Pediatric Cardiology, 4501Leiden University Medical Center, Leiden, the Netherlands.Pediatric Intensive Care Unit, 4501Leiden University Medical Center, Leiden, the Netherlands.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

36300272

Citation

Siersma, Carolien, et al. "Treatment of Post-Coarctectomy Hypertension With Labetalol-A 9-Year Single-Center Experience." World Journal for Pediatric & Congenital Heart Surgery, vol. 13, no. 6, 2022, pp. 701-706.
Siersma C, Brouwer CNM, Sojak V, et al. Treatment of Post-Coarctectomy Hypertension With Labetalol-A 9-Year Single-Center Experience. World J Pediatr Congenit Heart Surg. 2022;13(6):701-706.
Siersma, C., Brouwer, C. N. M., Sojak, V., Ten Harkel, A. D. J., & Roeleveld, P. P. (2022). Treatment of Post-Coarctectomy Hypertension With Labetalol-A 9-Year Single-Center Experience. World Journal for Pediatric & Congenital Heart Surgery, 13(6), 701-706. https://doi.org/10.1177/21501351221111797
Siersma C, et al. Treatment of Post-Coarctectomy Hypertension With Labetalol-A 9-Year Single-Center Experience. World J Pediatr Congenit Heart Surg. 2022;13(6):701-706. PubMed PMID: 36300272.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of Post-Coarctectomy Hypertension With Labetalol-A 9-Year Single-Center Experience. AU - Siersma,Carolien, AU - Brouwer,Carole N M, AU - Sojak,Vladimir, AU - Ten Harkel,Arend D J, AU - Roeleveld,Peter P, PY - 2022/10/27/entrez PY - 2022/10/28/pubmed PY - 2022/10/29/medline KW - aortic operation KW - coarctation KW - congenital heart surgery KW - database KW - intensive care KW - pediatric SP - 701 EP - 706 JF - World journal for pediatric & congenital heart surgery JO - World J Pediatr Congenit Heart Surg VL - 13 IS - 6 N2 - BACKGROUND: Although considering the pathophysiology of post-coarctectomy hypertension, β-blockers should be effective, experience with labetalol for treatment is limited in the literature. METHODS: Retrospective collection and analysis of data in children aged ≤6 years following coarctectomy in our tertiary care university medical center between January 2009 and June 2018. RESULTS: 96 patients were included, 45 were treated with intravenous labetalol and 51 received no treatment. Median time to maximum dose received (median 1.1 mg/kg/h) was 2.7 h, and median time to the reduction of labetalol dose was 8.3 h. No antihypertensives had to be added. In one child, labetalol was switched to nitroprusside due to bronchoconstriction. Of patients receiving intravenous labetalol, 48% had been switched to oral labetalol at discharge. CONCLUSIONS: Intravenous labetalol is a fast, effective, and safe drug to treat hypertension following aortic coarctation repair. Labetalol is easily converted to oral therapy when the continuation of treatment is considered necessary. SN - 2150-136X UR - https://www.unboundmedicine.com/medline/citation/36300272/Treatment_of_Post-Coarctectomy_Hypertension_With_Labetalol-A_9-Year_Single-Center_Experience. DB - PRIME DP - Unbound Medicine ER -